Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Beckmann

Showing results (821-830 of 1,041) with videos related to

Pageof 105
Sort By:
International Journal of Cancer|March 23, 2019
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patientsNaiba Nabieva, Lothar Häberle, Sara Y Brucker, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 11, 2012
Polymorphisms in inflammation pathway genes and endometrial cancer riskRyan J Delahanty, Yong-Bing Xiang, Amanda Spurdle, et al.
Breast (Edinburgh, Scotland)|January 21, 2020
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patientsC C Hack, L Häberle, S Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde|January 9, 2015
Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM StudyP A Fasching, T Fehm, S Kellner, et al.
Breast Cancer Research : BCR|August 16, 2015
A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic densityAnja Rudolph, Peter A Fasching, Sabine Behrens, et al.
Breast Cancer Research : BCR|October 8, 2016
Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association ConsortiumTaru A Muranen, Carl Blomqvist, Thilo Dörk, et al.
Breast Care (Basel, Switzerland)|December 7, 2016
Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyPaul Gaß, Peter A Fasching, Tanja Fehm, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2018
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM studyN Nabieva, T Fehm, L Häberle, et al.
Integrative Cancer Therapies|September 16, 2016
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyCarolin C Hack, Peter A Fasching, Tanja Fehm, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patientsN Nabieva, S Kellner, T Fehm, et al.
Pageof 105

Showing results (821-830 of 1,041) with videos related to

Sort By:
Pageof 105
International Journal of Cancer|March 23, 2019
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patientsNaiba Nabieva, Lothar Häberle, Sara Y Brucker, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 11, 2012
Polymorphisms in inflammation pathway genes and endometrial cancer riskRyan J Delahanty, Yong-Bing Xiang, Amanda Spurdle, et al.
Breast (Edinburgh, Scotland)|January 21, 2020
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patientsC C Hack, L Häberle, S Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde|January 9, 2015
Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM StudyP A Fasching, T Fehm, S Kellner, et al.
Breast Cancer Research : BCR|August 16, 2015
A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic densityAnja Rudolph, Peter A Fasching, Sabine Behrens, et al.
Breast Cancer Research : BCR|October 8, 2016
Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association ConsortiumTaru A Muranen, Carl Blomqvist, Thilo Dörk, et al.
Breast Care (Basel, Switzerland)|December 7, 2016
Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyPaul Gaß, Peter A Fasching, Tanja Fehm, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2018
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM studyN Nabieva, T Fehm, L Häberle, et al.
Integrative Cancer Therapies|September 16, 2016
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyCarolin C Hack, Peter A Fasching, Tanja Fehm, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patientsN Nabieva, S Kellner, T Fehm, et al.
Pageof 105